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ABSTRACT 
PET scanning, because of its impressive sensitivity and accuracy, is being incorporated into the standard staging 
workup for many cancers. These include lung cancer, lymphomas, head and neck cancers, and oesophageal cancers. PET 
often provides incremental information about the patient’s disease status, adding to the data obtained from structural 
imaging methods, such as, CT scan or MRI. PET commonly upstages patients into more advanced disease categories. 
Incorporation  of  PET  information  into  the  radiotherapy  planning  process  has  the  potential  to  reduce  the  risks  of 
geographic miss and can help minimise unnecessary irradiation of normal tissues. The best means of incorporating PET 
information into radiotherapy planning is uncertain, and considerable effort is being expended in this area of research. 
©2007 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
To plan and deliver “radical” (or potentially curative) 
radiotherapy  accurately  for  patients  with  malignant 
tumours,  the  locations  of  the  tumour  and  the  tumour-
bearing lymph nodes in three-dimensional space must be 
known. In addition, the relation of tumour to the anatomy 
of critical adjacent  normal tissues  must be considered. 
Conventional  three-dimensional  imaging  modalities, 
such as, CT or MRI scanning have serious limitations in 
determining the true extent of tumour in many clinical 
situations.  The  advent  of  PET  scanning  has 
revolutionised our approach to many cancers, and it is 
beginning  to  have  a  major  impact  on  radiotherapy 
planning at those centres where there is good access to 
this new imaging technology. Rapid changes have also 
been  occurring  in  the  technology  of  radiotherapy  in 
recent  years  [1].  Highly  advanced  treatment  planning 
systems now enable much more accurate and rapid three-
dimensional  radiation  dose  calculations.  These  permit 
quantitative  volumetric  assessment  of  dose  distribution 
both in tumour and critical normal tissues [2]. Ionising 
radiation  can  now  be  delivered  accurately  to  complex 
three dimensional shapes using linear accelerators with 
independently-controlled  multileaf  collimators.  The 
beam of radiation can be dynamically shaped during the 
course  of  treatment  delivery  [3].  Highly  flexible 
techniques,  such  as,  Intensity-Modulated  Radiotherapy 
(IMRT) are available [4], making it possible to shape the 
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high  dose  volumes  in  complex  ways.  Therefore,  the 
radiation  dose  may  be  escalated  without  increased 
toxicity [5], or the existing local control rates  may be 
maintained with reduced toxicity [6]. 
CT  scanning  is  the  primary  imaging  modality  for 
three-dimensional  radiotherapy  planning.  It  not  only 
provides  important  three-dimensional  anatomic 
information,  but  also  forms  the  basis  for  radiation 
dosimetry  by  reconstruction  of  a  three  dimensional 
electron-density map. This map is crucial for calculating 
radiation  absorption  and  scatter.  Unfortunately,  the 
information  that  CT  scanning  can  provide  about  the 
location of the tumour is often insufficient by itself to 
accurately guide treatment. When tumours have similar 
imaging characteristics to surrounding normal tissues, as 
is  often  the  case  for  lesions  in  the  oesophagus,  liver, 
spleen,  or  salivary  glands,  they  may  be  completely 
invisible on CT. Geographic miss and ultimate treatment 
failure  may  be  inevitable,  or  excessive  dose  may  be 
delivered to regions that do not contain tumour. Accurate 
lymph  node  staging  is  crucial  for  treating  moderately 
advanced cancers with curative intent [7, 8]. CT is often 
a poor investigation technique for lymph node staging, 
because  nodal  size  alone  is  the  criterion  for  assessing 
tumour  involvement.  Sensitivity  for  detection  of  small 
nodes containing tumour is very low, and false positives 
commonly  occur  due  to  benign  reactive 
lymphadenopathy [9].  
Staging  with  PET,  primarily  using 
18F-
fluorodeoxyglucose (FDG), has rapidly acquired a  key 
role in the management of cancers, such as, non-small 
cell lung cancer (NSCLC) [10, 11], Hodgkin and non-
Hodgkin  lymphomas  [12,  13],  head  and  neck  cancers, 
oesophageal  cancers  [14,  15],  and  cervical  carcinomas 
[16,  17].  It  is  also  effective  for  imaging  malignant 
melanoma  [18,  19],  soft  tissue  sarcoma  [20], 
gastrointestinal  cancers  [21],  and  some  other  less 
common  cancer  types  [22,  23].  Information  from  PET 
can  improve  the  results  of  radical  radiation  therapy 
simply  by  better  selection  of  patients.  Significantly 
improved  survival  has  already  been  demonstrated  in 
patients with NSCLC. They were selected for radical RT 
using  PET,  compared  with  a  conventionally  staged 
control group [24], largely because patients with PET-
detected  metastases  and  advanced  locoregional  disease 
were denied futile aggressive therapy. Accurate imaging 
of  tumour  in  three-dimensions  using  PET  has  the 
potential to improve the quality of radiotherapy planning, 
minimise the risk of geographic miss, and allow normal 
tissues  that  do  not  contain  gross  tumour  to  be  spared 
from  unnecessary  toxicity  [25].  As  PET  has  become 
more widely used by radiation oncologists, the question 
has  arisen  “What  is  the  best  method  for  incorporating 
PET  information  into  treatment  planning?”  In  the 
following  sections,  some  aspects  of  RT  planning  with 
PET will be considered and examples will be given of 
how  PET  can  influence  radiation  oncology  practice  in 
common thoracic cancers. 
PET AND THE RADIOTHERAPY PLANNING PROCESS  
Manufacturers of treatment planning systems have 
become  aware  of  the  need  to  accommodate  the 
importation  and  display  of  PET  information  in 
radiotherapy  planning  systems.  The  most  up  to  date 
systems  allow  integration  of  PET-CT  information 
directly into the RT contouring workstation. PET and CT 
information  can  readily  be  combined  to  produce  a 
Biological Target Volume (BTV) [26], incorporating all 
available  structural  and  functional  imaging.  For  lung 
cancer  and  several  other  malignancies,  possibly 
including  oesophageal  cancer,  the  BTV  represents  the 
best target for high dose irradiation that we can currently 
define.  When  clinical  PET  first  become  available  to 
oncologists,  no  means  existed  for  incorporating  PET 
information directly into the treatment planning process. 
Typically, PET and diagnostic CT images were simply 
displayed side by side on a light box and the Radiation 
Oncologist  would  visually  incorporate  the  PET 
information  when  contouring  the  GTV.  This  method 
works quite well for anatomical structures that are well-
demarcated on CT. However, it is not a good method for 
helping to delineate the boundaries of larger FDG-avid 
tumours that have interfaces with normal tissues where 
there  is  low  CT  contrast  between  tumour  and  normal 
tissue. To combine PET and CT data effectively in these 
cases,  it  is  necessary  to  devise  some  method  for 
displaying  PET  and  CT  information  simultaneously 
within the treatment planning software. 
Co-registration of separately-acquired PET and CT 
images for treatment planning  
At our own centre and at other institutions, in-house 
methods were developed for importing PET information 
into  the  radiotherapy  treatment  planning  system.  We 
developed a system that used fiducial markers, applied to 
the patient at separate CT and PET image acquisitions 
[27]. For both scans, patients were positioned identically 
by radiation therapists using lasers installed in both the 
CT and the PET suites. Phantom studies showed that the 
method was highly reproducible and could be utilised in 
clinical practice. DICOM PET information was imported 
into  the  radiotherapy  planning  system  (Cadplan)  and 
displayed side by side with the corresponding CT image, 
using software developed at our institution. This proved 
highly successful in practice, but with the installation of 
our  first  combined  PET/CT scanner,  it  has  since  been 
entirely superseded at our institution. This methodology 
is  still  widely  used  as  PET/CT  scanners  are  less 
commonly used than stand-alone PET scanners, although 
the rate of growth of PET/CT availability is very high, 
especially in the US. 
Use of integrated PET/CT for treatment planning 
The modern combined PET/CT scanner provides the 
best means for determining the BTV and for planning RT 
in those cancers that are well imaged by PET. Because 
PET and CT images are acquired on the same gantry, M MacManus et al. Biomed Imaging Interv J 2007; 3(1):e4    3 
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there  is  no  need  for  repositioning  the  patient.  This 
represents  a  major  advance  on  all  older  methods. 
Planning  systems,  such  as,  Focalease  and  Pinnacle 
enable  seamless  transfer  of  PET/CT  data  into  the 
contouring  workspace  and  provide  a  wide  range  of 
options  for  display  of  fused  PET  and  CT  images.  For 
treatment planning, the PET/CT scanner should be fitted 
with a rigid couch top and the imaging suite should be 
equipped with a laser positioning system, identical to that 
used for simulation and RT treatment. Patients should be 
scanned  in  the  treatment  position  with  immobilisation 
devices  fitted  and  ideally  under  the  supervision  of  a 
radiation  therapist/therapy  radiographer.  Following  the 
scan,  the  PET/CT  data  can  be  transmitted  to  the 
treatment planning system in DICOM format. 
Delineation of Biological Target Volumes 
After  the  PET/CT  data  are  imported  into  the 
planning computer, the radiation oncologist is faced with 
a series of new challenges. How do I define the gross 
tumour volume (GTV) using PET and CT? What nodes 
should I regard as positive? How do I define the edge of 
a tumour when it imperceptibly fades into normal tissues? 
How do I account for tumour movement? There has been 
little  guidance  from  the  literature  on  how  best  to  use 
PET/CT  information  in  contouring  tumour  and  target 
volumes. Some problems are relatively easy to deal with; 
a lymph node that is negative for tumour by CT criteria, 
but  is  unequivocally  involved  on  PET,  can  easily  be 
incorporated into the target volume. For these decisions, 
the  opinion  of  an  experienced  nuclear  medicine 
physician  should  always  be  sought.  Changes  to  the 
perceived status of the thoracic lymph node stations have 
the biggest influence on changing target volumes in the 
treatment of NSCLC. Similarly, enlarged nodes that are 
not metabolically active on PET may be omitted from the 
GTV if considered unlikely to contain tumour, and this is 
simple to accomplish.  
The  boundaries  of  some  tumours  can  be  very 
difficult  to  define,  especially  those  that  do  not  have 
clearly delineated margins on CT component of PET/CT 
[28].  Motion  of  the  patient  on  the  couch  top,  which 
should  be  minimal  with  appropriate  positioning  and 
immobilisation,  and  internal  motion  also  contribute  to 
the  blurriness  of  PET  images.  Other  factors  that 
commonly cause difficulty include regions of low avidity 
in the tumour due to necrosis, the confounding effects of 
inflammation and infection that can give rise to intense 
uptake  well  within  the  range  of  standardised  uptake 
value (SUV) seen in tumours, and poor contrast between 
tumours with a low SUV and adjacent normal structures. 
PET information is acquired over many respiratory and 
cardiac cycles and, therefore, an  “average” position of 
the  structures  is  imaged.  In  contrast,  CT  image  is 
acquired  virtually  instantaneously  and  usually  at  a 
random phase of the respiratory cycle.  
Because of the potential for inter-observer variation 
in using PET to determine target volumes for RT, several 
methods have evolved that attempt to make the results as 
uniform as possible. These are essentially either visual 
methods  using  the  skill  of  the  human  observer  or 
automated  methods  using  a  mathematical  algorithm  to 
contour  the  edge  of  the  tumour  in  a  reproducible  and 
unbiased way. Worldwide, the most common approach 
to  contouring  is  the  visual  one,  using  the  skill  of  the 
observer,  and  this  is  the  method  of  choice  at  our 
institution. At the Peter MacCallum Cancer Centre, RT 
planning  PET/CT  data  are  displayed  using  uniform 
window  settings  and  colour  settings.  All  available 
information is used in an “intelligent” process, including 
PET  and  CT  data,  biopsy  reports,  and  the  results  of 
fluoroscopy to assess tumour movement. We draw upon 
our  institutional  experience  of  comparing  individual 
PET/CT  scan  information  with  surgical  findings  in 
operable  cases  to  assist  our  interpretation  of  the  PET 
scan.  We  recognise  the  limits  of  the  training  and  the 
experience  of  radiation  oncologists  in  PET.  Therefore, 
contouring  of  the  GTV  is  only  carried  out  following 
consultation with the nuclear medicine physician, who is 
asked to draw around the edge of the tumour on a hard 
copy of the PET/CT scan. Uniform training and detailed 
guidelines  are  used  to  minimise  bias  in  this  process, 
although  the  final  interpretation  of  the  scan  is  always 
reliant  on  the  judgement  of  a  PET  physician.  As  an 
alternative to marking a hard copy, the PET Physician 
may be present in the radiotherapy planning area at the 
start of planning. Preliminary, so far unpublished, results 
of a reproducibility study at our centre suggest that this 
approach gives very similar results whether the GTV is 
contoured by a radiologist, PET physician, or Radiation 
Oncologist.  The  level  of  reproducibility  is  extremely 
high. This is in contrast to the poor results seen at other 
centres when CT alone is used for contouring, suggesting 
that PET/CT images are easier to interpret. 
An  alternative  approach  to  contouring  recognises 
that visual methods require a high level of human skill 
and experience and might exhibit significant variability 
between  observers.  This  approach  makes  use  of  the 
quantitative  information  available  from  PET.  Various 
automated  or  semi-automated  approaches  are  under 
evaluation for tumour contouring [26, 29-31], but none 
of  these  methods  has  yet  proven  to  be  a  trustworthy 
solution to the problem in vivo [32]. This method can 
produce good results with static phantoms [33] because 
FDG uptake is a result not only of malignant processes, 
but  can  arise  due  to  a  range  of  inflammatory  and 
physiological processes. A simple FDG intensity map or 
a function derived from it cannot be a general solution 
for  contouring.  Some  processes  that  can  be  readily 
recognised by an experienced physician (e.g., uptake in 
brown fat or muscle, sarcoidosis) have the potential to 
confound a purely quantitative approach. An increase in 
reproducibility  could  potentially  lead  to  a  decrease  in 
accuracy unless each computer-derived tumour contour 
is  edited  by  the  Radiation  Oncologist,  correcting 
instances  where  normal  or  benign  areas  of  uptake  are 
wrongly interpreted as tumour by the software. M MacManus et al. Biomed Imaging Interv J 2007; 3(1):e4    4 
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Movement 
Tumours  in  living  subjects  are  not  stationary,  but 
move to varying degrees within the patient. This internal 
range of movement is referred to as the Internal Target 
Volume  or  ITV  [31,  33].  The  ITV  is  often  well-
appreciated  on  PET  scanning  because  of  the  long 
acquisition time. Metabolically active lesions are usually 
qualitatively  elongated  in  the  axes  of  respiratory 
movement  compared  with  their  true  dimensions, 
reflecting  temporal  blurring  of  activity,  unless  the  CT 
image is acquired using some form of gating. Due to the 
lesion  spending  relatively  less  time  at  the  extremes  of 
respiratory  excursion,  particularly  at  the  end  of 
inspiration, activity tends to be less intense in those axial 
planes where the tumour spends proportionally less time. 
The  PET-determined  volume,  therefore,  indicates  very 
clearly the region where a tumour spends maximum time. 
Consequently, a treatment based on the PET determined 
GTV is likely to be more accurate than a treatment based 
on a randomly acquired CT image [34] [35]. 
SPECIFIC EXAMPLES OF THE ROLE OF PET IN 
RADIATION THERAPY PLANNING  
Non-Small Cell Lung Cancer 
Lung cancer is the  malignancy in  which PET has 
had  the  greatest  impact  on  selection  of  patients  for 
radiotherapy  and  on  radiotherapy  planning  [36].  This 
relates both to the clarity of imaging of a metabolically 
active cancer in a location favourable for PET and to the 
high rate of incremental abnormal findings seen on PET, 
compared with conventional imaging [37]. There is an 
abundance  of  evidence  from  surgical  series,  with 
systematic clinico-pathological correlation, proving that 
PET is much more accurate than CT in the assessment of 
thoracic  lymph  nodes,  especially  when  CT  and  PET 
information  are  combined.  Dwamena  and  colleagues 
reviewed  English-language  reports  on  the  performance 
of PET (14 studies, 514 patients) and/or CT (29 studies, 
2,226 patients) [38]. They reported that FDG-PET was 
significantly  more  accurate  than  CT  (P  <  .001).  Mean 
sensitivity  was  0.79  for  PET  vs  0.60  for  CT.  Mean 
specificity was 0.91 PET vs 0.77 for CT. These data can 
be  extrapolated  to  radiotherapy  candidates,  for  whom 
mediastinoscopy is usually not performed if the patient 
clearly  has  unresectable  disease  on  the  basis  of  CT 
findings or is medically unfit for surgery. PET has had 
the greatest impact on RT planning in patients for whom 
PET shows different lymph node status from CT, most 
commonly upstaging the extent of apparent nodal disease. 
A high impact is also seen in patients with atelectasis, 
where  the  boundary  between  tumour  and 
collapsed/consolidated lung can only be identified with 
the aid of PET [39].  
A  number  have  studies  have  tried  to  quantify  the 
impact of PET on RT planning in NSCLC. In our own 
earliest study, we used PET rather that PET/CT and had 
no  ability  to  co-register  images  [10].  Despite  those 
limitations, we found that 22 out of 102 patients had a 
significant increase in RT target volumes to cover new 
sites  of  disease  seen  only  on  PET.  In  16 patients,  the 
target  volume  was  reduced  because  regions  of  bland 
atelectasis could be excluded or enlarged nodes proved 
not  to  be  FDG-avid.  In  1998,  Nestle  and  Colleagues 
reported that a significant increase in the radiation field 
was required to cover PET detected disease in 9% of 34 
patients,  but  a  significant  decrease  was  seen  in  26%, 
especially  those  with  atelectasis  [39].  Munley  and 
colleages  recorded  that  35%  of  35  patients  had  an 
increase in the  RT field as  a result of PET [40]. In a 
larger  study  of  73  patients,  Vanuytzel  and  colleagues 
found  that  there  was  an  increase  in  GTV  in  22%  of 
patients and a decrease in 40% [41]. Other significant 
studies  include  work  by  Bradley  and  colleagues  who 
used  co-registered  sequential  PET  and  CT  scans  and 
reported  increased  GTV  in  46%  and  reduced  GTV  in 
12%  [42].  Brianzoni  and  colleagues  reported  that 
GTV/CTV was increased in 44% and reduced in 6% of 
24  lung  cancer  patients  planned  using  a  dedicated 
PET/CT scanner [43].  
Oesophageal Cancer 
Oesophageal  cancers  are  usually  locally  and  /or 
regionally  advanced  at  presentation,  and  only  a  small 
proportion  (20%)  of  patients  can  be  cured  by  surgery 
alone. Combined chemoradiation with or without surgery 
is commonly used to treat this disease, and the use of 
concurrent  chemoradiation  has  been  found  to 
significantly  increase  overall  survival  and  cure  rates 
compared with radiotherapy alone. As with lung cancer, 
CT is usually relied upon to determine the target volume 
for radiotherapy, and incorporation of PET data into RT 
planning has the potential to improve the accuracy of the 
process [44]. Although the radial extent of oesophageal 
tumours  can  usually  be  defined  with  CT,  it  is  well 
recognised that the longitudinal extent is more difficult 
to  define.  This  problem  is  compounded  by  the  rising 
incidence  of  adenocarcinoma  of  the  distal  oesophagus 
and gastro-oesophageal junction where the distal extent 
of the tumour (often in the cardia of the stomach) can at 
times be impossible to visualise on CT. CT is also often 
inaccurate  when  used  to  estimate  the  extent  of  nodal 
involvement. PET is significantly more accurate than CT 
for the assessment of nodes [45] that are not immediately 
adjacent  to  the  oesophagus  and  can  more  accurately 
delineate the longitudinal extent of tumour than CT. This 
is  especially  useful  in  cases  where  an  endoscope  is 
unable  to  pass  through  a  stenosed  oesophagus  to 
visualise the lower boundary of the tumour.  
Our group has demonstrated that FDG PET has a 
significant  impact  on  patient  management  in  a  multi-
disciplinary  setting  both  in  selecting  patients  for 
neoadjuvant chemoradiation [46] and also following it, 
but prior to definitive surgery [47]. In both these settings, 
the  findings  on  FDG  PET  were  strongly  predictive  of 
survival,  irrespective  of  management  chosen.  Results 
from  a  prospectively  conducted  trial  of  PET  in  RT 
planning, also conducted at our centre, show that PET 
has  a  significant  impact  on  RT  target  volumes  in M MacManus et al. Biomed Imaging Interv J 2007; 3(1):e4    5 
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oesophageal  cancer  [48].  In  our  cohort  of  patients  the 
GTV based on CT data alone excluded PET-avid disease 
in 69% of patients. In 31% of patients this would have 
resulted in a geographic miss due to inadequate coverage 
of  the  primary  oesophageal  tumour  and  exclusion  of 
unsuspected  nodal  disease  from  the  irradiated  volume. 
An example of a patient where CT and PET/CT target 
volumes differed significantly is shown in figure 1. In 
another study, Moureau-Zabotto and colleagues reported 
that  the  addition  of  PET  information  to  CT-based  RT 
planning  altered  the  GTV  in  19 of  34 patients  (56%), 
with a reduction in the GTV in 12 patients (35%) and an 
increase in 7 (21%) [49]. These promising results suggest 
that routine incorporation of PET data into radiotherapy 
planning  could  improve  the  results  of  treatment  for 
oesophageal carcinoma. 
CONCLUSION 
Even  the  most  sceptical  radiation  oncologist 
becomes  an  enthusiast  for  PET  when  this  technology 
becomes available for RT treatment planning. The very 
high rate of incremental information and the increased 
accuracy associated with this powerful imaging modality 
are rapidly changing our approach to some of the most 
common cancers. It is essential that we work hard to find 
the best ways to incorporate this new information into 
our everyday practice. 
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